Biogen Idec: Tecfidera not cause of patient's death

Share this article:

Biogen Idec said the death of a patient in July was not caused by its MS drug Tecfidera, reported the Wall Street Journal, which says the patient's physician came to this conclusion.

The patient had taken Tecfidera but stopped her regimen two-and-a-half weeks before she died, due to side effects including vomiting and diarrhea. Biogen Idec told Pharmalot at the time that this was important to note because the death was not “GI related.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.